DNMT1 and non-small cell lung carcinoma: demonstrated that the DNMT1 inhibitor 5‐azacytidine (5‐Aza), when combined with gefitinib or osimertinib, effectively restored drug sensitivity in non‐small cell lung cancer (NSCLC) patients [25].